Abstract
Paediatric epilepsy is a multifaceted neurological disorder with various aetiologies. Up to one third of patients are considered drug-resistant. The background impact of interfering inflammatory and neuronal pathways was closely linked to paediatric epilepsy. The characteristics of the inflamed state have been described not only in epilepsies, considered prototypes of having inflammatory pathophysiology, but even so in patients with refractory epilepsy, especially in epileptic encephalopathies. The imbalance of different cytokine levels was confirmed in several epileptic models. New targets for exploring neuroimmune mechanism in epileptogenesis are chemokines, which control leukocyte migration and have a possible role in neuromodulation. We measured serum interictal quantitative levels of chemokine CCL11 in correlation with seizure frequency and severity in controlled and refractory childhood epilepsies. Our refractory seizure group demonstrated significantly increased concentrations of eotaxin [CCL11] compared to the controlled epilepsy group. The higher level of CCL11 was correlated with increased seizure frequency. Thus our study confirms the hypothesis that proinflammatory cytokines may contribute to epileptogenesis and possibly have a role in developing seizure resistance.
References
Aaberg KM, Gunnes N, Bakken IJ, et al. Incidence and Prevalence of Childhood Epilepsy: A Nationwide Cohort Study. Pediatrics. 2017;139[5]:e20163908 ;
Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy — United States, 2015. MMWR. 2017; 66:821–825. DOI: 10.15585/mmwr.mm6631a1.
Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics 2012; 129:256-264. DOI: 10.1542/peds.2010-1371.
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug-resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51[6]:1069–1077.
Kalser J, Cross JH. The epileptic encephalopathy jungle - from Dr West to the concepts of aetiology-related and developmental encephalopathies. Curr Opin Neurol. 2018 Apr;31[2]:216-222. doi: 10.1097/WCO.0000000000000535. PMID: 29356691
Johannessen Landmark C, Potschka H, Auvin S, Wilmshurst JM, Johannessen SI, Kasteleijn-Nolst Trenité D, Wirrell EC. The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results. Epilepsia. 2021 Apr;62[4]:857-873. doi: 10.1111/epi.16849. Epub 2021 Feb 27. PMID: 33638459.
Nicola Specchio, Elaine C. Wirrell, Ingrid E. Scheffer, Rima Nabbout, Kate Riney, Pauline Samia, Marilisa Guerreiro, Sam Gwer, Sameer M. Zuberi, Jo M. Wilmshurst, Elissa Yozawitz, Ronit Pressler, Edouard Hirsch, Samuel Wiebe, Helen J. Cross, Emilio Perucca, Solomon L. Moshé, Paolo Tinuper, Stéphane Auvin, International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions, Epilepsia, 2022, 10.1111/ epi.17241, 63, 6, [1398-1442]
Van Vliet, E. A., Aronica, E., Vezzani, A. & Ravizza, T. Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies. Neuropathol. Appl. Neurobiol. 2018, 44, 91–111
Mehta V, Ferrie CD, Cross JH, Vadlamani G. Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms. Cochrane Database Syst Rev. 2015 Jun 18;2015[6]:CD005222. doi: 10.1002/14651858.CD005222.pub3. PMID: 26086765; PMCID: PMC7390481.
Vezzani, A., Lang, B. & Aronica, E. Immunity and inflammation in epilepsy. Cold Spring Harb. Perspect. Med. 2015, 6, a022699
Kim I, Mlsna LM, Yoon S, et al. A postnatal peak in microglial development in the mouse hippocampus is correlated with heightened sensitivity to seizure triggers. Brain and behavior. 2015; 5[12]:e00403
Lisa Gillinder, Pamela McCombe, Tamara Powell, Gunter Hartel, David Gillis, Ingrid Leal Rojas, Kristen Radford, Cytokines as a marker of central nervous system autoantibody associated epilepsy, Epilepsy Research, 10.1016/j.eplepsyres. 2021 , 2021.106708, 176, [106708]
Uludag IF, Bilgin S, Zorlu Y, Tuna G, Kirkali G. Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure. 2013; 22[6]:457–61. doi:10.1016/j.seizure.2013.03.004.
Pernhorst K, Herms S, Hoffmann P, Cichon S, Schulz H, Sander T, et al. TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure frequency in human epileptic brain tissue. Seizure. 2013, 22[8]:675–8. doi:10.1016/ j.seizure.2013.04.023.
Mao LY, Ding J, Peng WF, Ma Y, Zhang YH, Fan W, et al. Interictal interleukin-17A levels are elevated and correlate with seizure severity of epilepsy patients. Epilepsia. 2013, 54[9]:e142–5. doi:10.1111/epi.12337
Egunsola O, Choonara I, Sammons HM, Whitehouse WP. Safety of antiepileptic drugs in children and young people: A prospective cohort study. Seizure. 2018 Mar;56: 20-25. doi: 10.1016/j.seizure.2018.01.018
Aulická S, Èeská K, Šána J, Siegl F, Brichtová E, Ošlejšková H, Hermanová M, Hendrych M, Michu EP, Brázdil M, Slabý O, Nestrašil I. Cytokine-chemokine profiles in the hippocampus of patients with mesial temporal lobe epilepsy and hippocampal sclerosis. Epilepsy Res. 2022, Feb;180:106858. doi: 10.1016/j.eplepsyres.2022.106858.
Arisi GM. Nervous and immune systems signals and connections: Cytokines in hippocampus physiology and pathology. Epilepsy Behav. 2014;. doi:10.1016/ j.yebeh.2014.01.017.
Thambi M, Nathan J, Bailur S, Unnikrishnan MK, Ballal M, Radhakrishnan K. Is the antiseizure effect of ketogenic diet in children with drug-resistant epilepsy mediated through proinflammatory cytokines? Epilepsy Res. 2021 Oct;176:106724. doi: 10.1016/j.eplepsyres.2021.106724.38
Ransohoff RM. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity. 2009, Nov 20;31[5]:711-21. doi: 10.1016/ j.immuni.2009.09.010.
Aulická S, Èeská K, Šána J, Siegl F, Brichtová E, Ošlejšková H, Hermanová M, Hendrych M, Michu EP, Brázdil M, Slabý O, Nestrašil I. Cytokine-chemokine profiles in the hippocampus of patients with mesial temporal lobe epilepsy and hippocampal sclerosis. Epilepsy Res. 2022, Feb;180:106858. doi: 10.1016/j.eplepsyres.2022.106858.
Cerri C, Caleo M, Bozzi Y. Chemokines as new inflammatory players in the pathogenesis of epilepsy. Epilepsy Res. 2017, Oct;136:77-83. doi: 10.1016/j.eplepsyres.2017.07.016
Kenney MJ, Ganta CK. Autonomic nervous system and immune system interactions. Compr Physiol. 2014, Jul;4[3]:1177-200. doi: 10.1002/cphy.c130051. PMID: 24944034; PMCID: PMC4374437.
Li L, Yu Y, Hou R, Hao J, Jiang J. Inhibiting the PGE2 Receptor EP2 Mitigates Excitotoxicity and Ischemic Injury. ACS Pharmacol Transl Sci. 2020, Jun 25;3[4]:635-643. doi: 10.1021/acsptsci.0c00040.
Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada EY, et al. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther 2007, 323: 488–98
Moavero R, Santarone ME, Galasso C, Curatolo P. Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain Dev. 2017, Jun;39[6]:464-469. doi:10.1016/j.braindev.2017.01.006.
Choonara I. Anti-Epileptic Drug Toxicity in Children. Children [Basel]. 2018 May 1;5[5]:57. doi: 10.3390/chil- dren5050057.
Egunsola O, Choonara I, Sammons HM, Whitehouse WP. Safety of antiepileptic drugs in children and young people: A prospective cohort study. Seizure. 2018 Mar;56: 20-25. doi: 10.1016/j.seizure.2018.01.018
Knight R, Wittkowski A, Bromley RL. Neurodevelop- mental outcomes in children exposed to newer antiseizure medications: A systematic review. Epilepsia. 2021 Aug;62[8]:1765-1779. doi: 10.1111/epi.16953
Holmes GL. Cognitive impairment in epilepsy: the role of network abnormalities. Epileptic Disord. 2015, Jun;17[2] 101-16. doi: 10.1684/epd.2015.0739.
Poole BJ, Phillips NL, Stewart E, Harris IM, Lah S. Working Memory in Pediatric Epilepsy: A Systematic Review and Meta-Analysis. Neuropsychol Rev. 2021 Dec;31[4]:569-609. doi: 10.1007/s11065-021-09491-7.
Auvin S, Wirrell E, Donald KA, Berl M, Hartmann H, Valente KD, Van Bogaert P, Cross JH, Osawa M, Kanemura H, Aihara M, Guerreiro MM, Samia P, Vinayan KP, Smith ML, Carmant L, Kerr M, Hermann B, Dunn D, Wilmshurst JM. Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission. Epilepsia. 2018 Oct;59[10]:1867-1880. doi: 10.1111/epi.14549.
Kohrman MH. What is epilepsy? Clinical perspectives in the diagnosis and treatment. J Clin Neurophysiol. 2007, Apr;24[2]:87-95. doi: 10.1097/WNP.0b013e3180415b51.
O’Donoghue MF, Duncan JS, Sander JW. The National Hospital Seizure Severity Scale: a further development of the Chalfont Seizure Severity Scale. Epilepsia. 1996 Jun;37[6]:563-71. doi: 10.1111/j.1528-1157.1996.tb00610.x.
GAZE SCORE Chan CJ, Zou G, Wiebe S, Speechley KN. Global assessment of the severity of epilepsy [GASE] Scale in children: Validity, reliability, responsiveness. Epilep- sia. 2015 Dec;56[12]:1950-6. doi: 10.1111/epi.13216.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51[6]:1069-77. doi: 10.1111/j.1528-1167.2009.02397.x.
Helbig I, Tayoun AA. Understanding Genotypes and Phenotypes in Epileptic Encephalopathies. Mol Syndromol. 2016 Sep;7[4]:172-181. doi: 10.1159/000448530.
Galea I, Bechmann I, Perry VH. What is immune privilege [not]? Trends Immunol. 2007, Jan;28[1]:12-8. doi: 10.1016/ j.it.2006.11.004.
Tong Y., Yang T., Wang J., Zhao T., Wang L., Kang Y., Cheng C., Fan Y. Elevated plasma chemokines for eosino- phils in neuromyelitis optica spectrum disorders during remission. Front. Neurol. 2018; 9:44. doi: 10.3389/ fneur.2018.00044